Petra Rietschel

3.5k citations

54 papers · 1.5k indexed · 1 hit paper · h-index 12

Co-authors: Steven Grinspoon Colleen Hadigan Takara L. Stanley Colleen Corcoran Nesli Basgoz Paul B. Chapman Benjamin Davis Paul E. Sax
Topics: Lung Cancer Treatments and Mutations (35 papers)Cancer Immunotherapy and Biomarkers (31 papers)Colorectal Cancer Treatments and Studies (9 papers)
Cited by: Virology Emergency Medicine Infectious Diseases
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaAmerican Journal of Clinical Nutrition
Partner nations: United States Türkiye Ukraine

In The Last Decade

Petra Rietschel

49 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy

2001 549 citations Colleen Corcoran, Petra Rietschel et al. Clinical Infectious Diseases profile →

Peers

Countries citing papers authored by Petra Rietschel

Since Specialization

Citations

This map shows the geographic impact of Petra Rietschel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petra Rietschel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petra Rietschel more than expected).

Fields of papers citing papers by Petra Rietschel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petra Rietschel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petra Rietschel. The network helps show where Petra Rietschel may publish in the future.

Co-authorship network of co-authors of Petra Rietschel

This figure shows the co-authorship network connecting the top 25 collaborators of Petra Rietschel. A scholar is included among the top collaborators of Petra Rietschel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petra Rietschel. Petra Rietschel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial 2024 ·Lung Cancer ·(unknown),Tamta Makharadze,Miranda Gogishvili,Tamar Melkadze,(unknown),Konstantin Penkov,К. К. Лактионов,(unknown),Marina Nechaeva,Irina Rozhkova,Ewa Kalinka‐Warzocha,(unknown),Javier J. Pérez,Manika Kaul,Ruben G.W. Quek,Frank Seebach,Petra Rietschel,Jean‐François Pouliot	4
2	Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer 2023 ·Frontiers in Oncology ·Josephine Feliciano,(unknown),Yingxin Xu,Ruben G.W. Quek,Andreas Kuznik,Jean‐François Pouliot,Giuseppe Gullo,Petra Rietschel,Patricia Guyot,(unknown),(unknown),(unknown),(unknown),Nick Freemantle	5
3	Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3 2023 ·Cancer ·Tamta Makharadze,Ruben G.W. Quek,Tamar Melkadze,Miranda Gogishvili,Cristina Ivanescu,(unknown),Mikhail Dvorkin,Konstantin Penkov,К. К. Лактионов,(unknown),Marina Nechaeva,Irina Rozhkova,Ewa Kalinka‐Warzocha,Christian Geßner,Brizio Moreno‐Jaime,Rodolfo Passalacqua,(unknown),Petra Rietschel,Giuseppe Gullo	8
4	Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials. 2023 ·Journal of Clinical Oncology ·Joseph C. Murray,(unknown),Valsamo Anagnostou,Julie R. Brahmer,Alexander Meisel,Ahmet Sezer,Miranda Gogishvili,Tamar Melkadze,(unknown),Tamta Makharadze,(unknown),Siyu Li,Vladimir Janković,Frank Seebach,Petra Rietschel,Young J. Kim,Giuseppe Gullo,Jean‐François Pouliot	1
5	LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial 2022 ·Annals of Oncology ·Mustafa Özgüroğlu,Saadettin Kılıçkap,(unknown),(unknown),Igor Bondarenko,(unknown),Marina Nechaeva,(unknown),(unknown),Gwo Fuang Ho,(unknown),Mikhail Dvorkin,(unknown),(unknown),(unknown),(unknown),Frank Seebach,(unknown),(unknown),Petra Rietschel	7
6	112P Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation 2022 ·Annals of Oncology ·Igor Bondarenko,Ahmet Sezer,Saadettin Kılıçkap,Mahmut Gümüş,Mustafa Özgüroğlu,(unknown),Xiaodong He,(unknown),Petra Rietschel,Ruben G.W. Quek	1
7	Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy 2022 ·Cancer Management and Research ·Wenzhen Ge,Ning Wu,Jessica J. Jalbert,Ruben G.W. Quek,Jinjie Liu,Petra Rietschel,Jean‐François Pouliot,James Harnett,Melinda Laine Hsu,Josephine Feliciano	4
8	582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1 2022 ·Regular and Young Investigator Award Abstracts ·Saadettin Kılıçkap,Ahmet Sezer,(unknown),Igor Bondarenko,Mustafa Özgüroğlu,Miranda Gogishvili,(unknown),Giuseppe Gullo,Petra Rietschel,Ruben G.W. Quek	0
9	Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50% 2022 ·Therapeutic Advances in Medical Oncology ·Nick Freemantle,Yingxin Xu,(unknown),Patricia Guyot,Chieh-I Chen,(unknown),(unknown),(unknown),Andreas Kuznik,Kokuvi Atsou,(unknown),Jean‐François Pouliot,Giuseppe Gullo,Petra Rietschel	1
10	Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort 2021 ·Lung Cancer ·Víctor Moreno,Pilar Garrido,Kyriakos P. Papadopoulos,Maria J. de Miguel,Marta Gil-Martín,Raid Aljumaily,Lee S. Rosen,Petra Rietschel,Kosalai Kal Mohan,Suk‐Young Yoo,Elizabeth Stankevich,Israel Lowy,Matthew G. Fury	11
11	93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial 2021 ·Annals of Oncology ·Tamta Makharadze,Ruben G.W. Quek,Tamar Melkadze,Miranda Gogishvili,Cristina Ivanescu,(unknown),Mikhail Dvorkin,Konstantin Penkov,К. К. Лактионов,Gia Nemsadze,M. Nechaeva,(unknown),Ewa Kalinka‐Warzocha,Christian Geßner,Brizio Moreno‐Jaime,Rodolfo Passalacqua,(unknown),Petra Rietschel,Giuseppe Gullo	1
12	1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC) 2020 ·Annals of Oncology ·Byoung Yong Shim,(unknown),Javier de Castro,(unknown),Manuel Cobo,Hye Ryun Kim,Jeong‐Seon Ryu,M. Majem Tarruella,Yvonne Summers,Christian A. Thomas,Yadan Xu,Israel Lowy,Petra Rietschel	7
13	LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% 2020 ·Annals of Oncology ·Ahmet Sezer,Saadettin Kılıçkap,Mahmut Gümüş,Igor Bondarenko,Mustafa Özgüroğlu,Miranda Gogishvili,Hacı Mehmet Türk,(unknown),Dmitry Bentsion,Oleg Gladkov,Philip R. Clingan,Virote Sriuranpong,Naiyer A. Rizvi,(unknown),(unknown),Giuseppe Gullo,Israel Lowy,Petra Rietschel	20
14	P2.01-26 EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC 2019 ·Journal of Thoracic Oncology ·Miranda Gogishvili,Niloufar Mobashery,Tamta Makharadze,(unknown),P.J. Snodgrass,(unknown),Israel Lowy,Petra Rietschel,(unknown)	4
15	P3.04-26 EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50% 2018 ·Journal of Thoracic Oncology ·Naiyer A. Rizvi,(unknown),(unknown),(unknown),Bo Gao,Petra Rietschel	0
16	P3.04-24 EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study 2018 ·Journal of Thoracic Oncology ·Naiyer A. Rizvi,(unknown),(unknown),(unknown),Bo Gao,Petra Rietschel	1
17	P3.04-25 EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 <50% 2018 ·Journal of Thoracic Oncology ·Naiyer A. Rizvi,(unknown),(unknown),(unknown),Bo Gao,Petra Rietschel	2
18	MA04.01 Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts 2018 ·Journal of Thoracic Oncology ·Víctor Moreno,Marta Gil-Martín,Melissa L. Johnson,Raid Aljumaily,(unknown),(unknown),Marka R. Crittenden,Salma K. Jabbour,(unknown),Emiliano Calvo,Kyriakos P. Papadopoulos,Pilar Garrido,A. Hervás,Petra Rietschel,Kosalai Kal Mohan,(unknown),Elizabeth Stankevich,Feng Ma,Israel Lowy,Matthew G. Fury	14
19	Immunotherapy of Melanoma 2006 ·Hematology/Oncology Clinics of North America ·Petra Rietschel,Paul B. Chapman	12
20	Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral Therapy 2000 ·Clinical Infectious Diseases ·Petra Rietschel,Colleen Corcoran,Takara L. Stanley,Nesli Basgoz,Anne Klibanski,Steven Grinspoon	109

About Petra Rietschel

Petra Rietschel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Virology, having authored 54 papers that have together received 1.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (35 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Colorectal Cancer Treatments and Studies (9 papers). The work is most often cited by research in Virology (450 citations), Emergency Medicine (823 citations) and Infectious Diseases (513 citations). Petra Rietschel has collaborated with scholars based in United States, Türkiye and Ukraine. Frequent co-authors include Steven Grinspoon, Colleen Hadigan, Takara L. Stanley, Colleen Corcoran, Nesli Basgoz, Paul B. Chapman, Benjamin Davis, Paul E. Sax, Ralph B. D’Agostino and Peter W.F. Wilson. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and American Journal of Clinical Nutrition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact